CHICAGO — David K. Lee, CEO of Servier Pharmaceuticals, provided HemOnc Today with an overview of the company during ASCO Annual Meeting.
Servier Pharmaceuticals — founded in late 2018 — has approximately 100 employees, and the goal is to double the size of the business within the next 5 years.
The company has two marketed products for acute lymphoblastic leukemia, and the pipeline includes chimeric antigen receptor T-cell therapies, monoclonal antibodies and bispecifics.
Servier Pharmaceuticals is part of Servier Group, which is involved in other therapeutic areas such as cardiology, diabetes, immunoinflammatory diseases and neuroscience.
Servier Group is owned by a nonprofit foundation.
“We’re a private company, but what that really means is we can truly focus on the patients,” Lee told HemOnc Today. “We don’t have investors and don’t pay dividends. All money we make gets reinvested in the company, patients, and research and development.” – by Mark Leiser